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Results: Overall, 1082 target lesions were identified. The target lesions were A type
in 111 cases (10.3%), B1 in 201 (18.6%), B2 in 252 (23.3%), and C in 518 (47.9%).
Complete follow-up was available for 99.3% of the patients at 180 days, 99.1% at 360
days, and 99.1% at 540 days. A total of 17 deaths occurred during the 180 days (2.3%),
25 deaths occurred during the 360 days, and 27 deaths occurred during the 540 days.
In none of these cases, death occurred as an unexpected, sudden episode that could be
attributable to stent thrombosis. no patient had recurrent myocardial infarction, and
there were no additional reinterventions. Also, 5 thrombosis events by ARC definition
at 18-months were documented. The average duration of clopidogrel treatment was
180 days. The cumulative rates of major adverse cardiac events were 2.0% at 180 days,
3.9% at 1 year, and 4.2% at 18 months. Overall rate of stent thrombosis was 0.87% at
18 months. The rates of acute, subacute, late, and very late stent thrombosis were 0.1%,
0.38%, 0.34%, and 0.05%, respectively. Angiographic follow-up, performed in 974
(31.6%) lesions from 653 patients (31.7%), revealed a mean in-stent late lumen loss
of 0.21 ± 0.39 mm. Binary restenosis rates were 3.8% in-stent and 6.7% in-segment.
Conclusion: This multicenter registry documents satisfactory safety and efficacy
profiles, as evidenced by low rates of major adverse cardiac events and stent thrombosis
up to 18 months, for the Excel biodegradable polymer-based sirolimus-eluting stent.
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Background: Multislice computed tomography (MSCT) coronary angiography has
emerged as a non-invasive diagnostic modality to evaluate coronary artery disease.
However, visualization or evaluation of the in-stent lumen by MSCT is challenging
owing to the blooming artefact caused by metallic stent struts. The feasibility and
accuracy of the use of MSCT in the analysis of radiolucent bioresorbable scaffolds
could indicate a new era for non-invasive assessment of patients treated with
radiolucent devices.
Methods: The ABSORB Cohort B trial enrolled 101 patients at 12 sites in the
European and Asia Pacific regions between March and November 2009. The current
aim is to assess, by MSCT, the midterm results at 18 months in terms of patency and
absence of binary restenosis of the ABSORB bioresorbable everolimus eluting vascular
scaffold (Abbott Vascular, Santa Clara, CA, USA).
Results: In the smaller ABSORB Cohort A study, we have previously demonstrated
that non-invasive imaging of the ABSORB scaffold patency with MSCT is feasible
without the artifacts associated with conventional metal stents. In the ABSORB Cohort
B trial, clinical data up to 1 year for the full cohort of 101 patients are currently
available. In these 101 patients, 1 year results showed an ID-MACE rate of 6.9%. The
18-month clinical and MSCT results for the full cohort of 101 patients from the
ABSORB Cohort B trial will be presented.
Conclusion: Eighteen month data are currently being collected and we will present
18-month clinical and MSCT results for the full cohort of patients from the ABSORB
Cohort B trial.
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Background: Very small coronary vessels (reference diameter <2.5mm) are often
associated with diabetic and female patients and remain an important challenge in
interventional cardiology. We studied a large population of patients with very small
vessels treated with Nobori DES coated only abluminally with a matrix of biolimus
A9 and a biodegradable polymer.
Methods: We studied 1284 patients with at least one lesion located in a very small
vessel (SV) treated with Nobori stent. The primary endpoint of the study is target lesion
failure (TLF) defined as cardiac death, target vessel related myocardial infarction (MI)
and target lesion revascularization (TLR). Data are captured electronically with an
extensive monitoring (100% on-line and 30% on-site). An independent clinical event
committee adjudicated all adverse events and an independent corelab analyzes baseline
and adverse events angiograms.
Results: Patients were 65±11 years old, 23% were female, 34.8% had undergone
previous PCI treatment, 52.1% were admitted with acute coronary syndrome, 32.6%
were diabetic (7.6% insulin dependent) and more than 70% were hyperlipidemic and
hypertensive. A mean number of 1.96±1.18 stents were implanted per patient, with
1.67±0.86 lesions per patient treated. Direct stenting was performed in 27.7% of the
procedures and femoral access site was used in 61% of the patients. A total of 69% of
the lesions were complex (type B2+C), 26.4% calcified, 20.0% bifurcated, 10.6% ostial
and 6.3% presented ulceration. By QCA the mean RVD was 2.29±0.48mm. At 2 years,
94.7% of the patients were available for follow-up with reported TLF rate of 3.7% and
stent thrombosis rate of 0.8%.
Conclusion: Although very small vessels are considered challenging to treat and
represent a higher risk for adverse outcomes, this analysis showed very low rates of
TLF and stent thrombosis up to 2 years, indicating excellent efficacy and safety of the
Nobori stent in the treatment of very small vessels.
TCT-25
Bioresorbable Everolimus Eluting Vascular Scaffold in Small Vessels One year
results
Roberto Diletti1, Hector M Garcia-Garcia14, Vasim Farooq1, Yoshinobu Onuma1,
Salvatore Brugaletta1, Robert Jan van Geuns1, Evelyn Regar1, Bernard de Bruyne2,
Dariusz Dudek3, Leif Thuesen4, Bernard Chevalier5, Dougal McClean6, Stephan
Windecker7, Robert Whitbourn9, Pieter Smits8, Jacques Koolen10, Ian Meredith11,
Xiaolin Li13, Dong Li12, Susan Veldhof12, Richard Rapoza13, John A Ormiston15,
Patrick Serruys1
1Interventional Cardiology, Erasmus MC, Rotterdam, Netherlands; 2Cardiovascular
Center Aalst, Aalst, Belgium; 3Department of Cardiology, Jagiellonian University,
Krakow,, Poland; 4Department of Cardiology, Skejby Sygehus, Aarhus University
Hospital, Skejby, Denmark; 5Department of Cardiology, Institut Hospitalier Jacques
Cartier, Massy, France; 6Department of Cardiology, Christchurch Hospital,
Christchurch, New Zealand; 7Department of Cardiology, Bern University Hospital,
Bern, Switzerland; 8Maasstad ziekenhuis, Rotterdam, Netherlands; 9Department of
Cardiology, St Vincents Hospital, Melbourne, Australia; 10Catharina Ziekenhuis,,
Eindhoven, Netherlands; 11Monash Medical Centre, Victoria, Australia; 12Abbott
Vascular, Diegem, Belgium; 13Abbott Vascular, Santa Clara, CA; 14Cardialysis B.V.,
Rotterdam, Netherlands; 15Department of Cardiology, Auckland City Hospital,
Auckland, New Zealand
Background: The second generation Bioresorbable Everolimus Eluting Vascular
Scaffolds (BVS) are untested at the mid-term follow-up in the subset of small coronary
vessels. We investigated the performance of the second generation BVS (Abbott
Vascular, Santa Clara, CA) in small coronary arteries (<2.5mm) at 1-year follow-up
Methods: The ABSORB Cohort B Trial is a multicentre single-arm, prospective, open-
label trial enrolling 101 patients. In the present post-hoc analysis, the study population
was sorted according to the pre-procedural reference vessel diameter (RVD) into two
groups: 1) Small-vessel group with RVD <2.5mm (41 patients, 41 lesions) and 2)
Large-vessel group with RVD >=2.5 mm (60 patients, 61 lesions). Clinical outcomes
were assessed at one-year follow-up for the entire population and compared between
the two groups. Out of the total population 45 patients were assigned to undergo 6-
month coronary angiography and 56 patients (57 lesions) to have the procedure
performed at one year.
Results: At one-year after implantation no differences in Ischemia-Driven (ID) Major
Adverse Cardiovascular Events (small vessels 3/41 cases, 7.3% vs. large vessels 4/60
cases, 6.7%,p=1.0000), Myocardial Infarction (small vessels 2/41 cases, 4.9% vs large
vessels 1/60 case, 1.7%,p=0.5645) and ID-Target Lesion Revascularization (small
vessels 1/41 case, 2.4% vs large vessels 3/60 cases, 5.0%, p=0.6445) were reported
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between the two groups. No Cardiac Death was observed. At 1-year angiographic
follow-up, no differences were showed in late lumen loss (small vessels 0.27±0.32mm
vs. large vessels 0.27±0.32mm, p=0.9852) and In-Scaffold Binary Restenosis (small
vessels 0/21 cases, 0.0% vs large vessels 2/36 cases, 5.6% p=0.5263).
Conclusion: The second generation BVS showed similar clinical and angiographic
outcomes at 1-year follow-up in small and large vessels.
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Background: Late serious adverse events associated with next generation drug-eluting
stents require further evaluation. At 4 years the ENDEAVOR IV study, comparing the
Endeavor zotarolimus-eluting stent (E-ZES) with the Taxus paclitaxel-eluting stent
(PES) indicated similar efficacy and significantly lower rates of clinically-driven
myocardial infarction (MI) and very late stent thrombosis (ST).
Methods: ENDEAVOR IV was a multicenter, randomized (1:1), single-blind,
controlled trial that enrolled 1548 patients undergoing percutaneous revascularization
for a single de novo native coronary lesion. The primary endpoint at 9 months was
target vessel failure (TVF; cardiac death, MI or clinically-driven target vessel
revascularization [TVR]), and safety endpoints included cardiac death, MI and ARC-
defined ST.
Results: Baseline clinical and angiographic characteristics were similar between
groups. Four-year clinical outcomes are in the Table.
TLR, target lesion revascularization; MACE, major adverse cardiac events
Conclusion: The 4 year results demonstrated comparable efficacy (TLR and TVR) for
E-ZES compared with PES and an improved safety profile with lower VLST and fewer
MIs. The “final” 5-year results of the ENDEAVOR IV study will be presented.
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Background: The 2009 American College of Cardiology (ACC) Appropriate Use
Criteria (AUC) for Coronary Revascularization categorized percutaneous coronary
interventions (PCI) as appropriate (A), uncertain (U), or inappropriate (I) according to
180 clinical scenarios. ACC released AUC hospital summary reports for PCI in May
2011.
Methods: We developed an algorithm based on the AUC scenarios and calculated
patient scores for the two Portland hospitals in our Providence Health & Services
(PH&S) healthcare system. After this successful pilot we applied this algorithm to 11
other PH&S facilities using PCI data from July 2009 through December 2010
(n=12,203, 66% acute, 34% non-acute). Results from our algorithm were compared to
the ACC results for 2010. We determined the primary reasons for inappropriate ratings
and unclassifiable cases.
Results: After excluding two facilities with fewer than 100 PCIs, non-scorable cases
(16%) were primarily due to no stress test performed (37%) or unavailable stress test
results (56%). For the scorable cases, the averages (range) for A, U and I scores were:
89% (76-97%), 9% (2-19%) and 2% (1-5%), respectively, showing considerable
variation across the healthcare system. In non-acute patients alone, inappropriate scores
averaged 7% (0-13%) with the following most common reasons: suboptimal use of
medical therapy (96%), low to moderate angina symptoms with low-risk stress tests
(58%), and/or no angina with low to intermediate risk stress tests (40%). Our results
compared favorably to the ACC reports, with approximately 99% concordance.
Conclusion: Our analysis identified several important areas of focus: 1) rates of
suboptimal anti-anginal medical therapy; 2) referrals of low risk patients with low level
angina for revascularization; and 3) the role of stress testing in the revascularization
decision-making process.
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Background: In patients with severe, multivessel coronary disease, coronary artery
bypass grafting (CABG) has been considered the standard of care over percutaneous
coronary intervention (PCI). We will present 4 year outcomes in the 3VD subgroup of
patients in SYNTAX.
Methods: SYNTAX is a randomized clinical trial with parallel nested registries. A
cardiac surgeon and interventional cardiologist screened consecutive pts with de novo
3VD and/or LM disease. Randomization occurred if the patient was amenable to
equivalent revascularization using either treatment. Analysis of the 3VD patient cohort
was prespecified.
Results: : In the 3VD subgroup at 3 years, MACCE was significantly higher in PCI
compared with CABG patients. The rates of death/stroke/MI, death, MI and repeat
revascularization were increased in PCI pts; however, stroke was similar between
groups at 3 years (Table). Partitioning 3VD subgroup patients by SYNTAX Score
tercile demonstrated similar MACCE in patients with low scores (0-22: CABG 22.2%
vs PCI 25.8%, P=0.45); whereas MACCE was increased in patients with intermediate
scores (23-32: 16.8% vs 29.4%, P=0.003). Both MACCE and mortality were increased
in PCI patients with scores ≥33 (17.9% vs 31.4%, P=0.004 and 4.5% vs 11.1%,
P=0.03). Four-year outcomes will be available at the time of the presentation.
Conclusion: At 3 years, MACCE was significantly increased in PCI 3VD compared
with CABG-treated patients; In patients with less complex disease (low SYNTAX
Scores), PCI may be an acceptable revascularization option.
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Background: SYNTAX randomized patients with multivessel and/or left main disease
to PCI and CABG. Patients deemed ineligible for randomization by the heart team
were included in registries. Analysis of these patients is important to understand “real
world” strengths and limitations of PCI and CABG.
Methods: 4337 patients were screened in SYNTAX; 198 and 1077 patients were
included in respectively the PCI and CABG registries. All PCI registry patients and
649 randomly selected CABG registry patients were followed for major adverse cardiac
or cerebrovascular events (MACCE). Patients entered in the PCI registry were
considered inoperable, and in the CABG registry as non-treatable by PCI.
Results: Main reason for inclusion in the CABG registry was excessively complex
coronary anatomy unsuitable for PCI (70.9%). Major co-morbidities were main reasons
for PCI treatment (70.7%). PCI registry patients had a higher risk profile than
randomized patients (EuroSCORE 7.8 ± 9.0 vs 3.8 ± 2.6) but similar lesion complexity
(SYNTAX Score 31.6 ± 12.3 vs 28.4 ± 11.5). Three-year MACCE was 38.0% after
PCI. CABG registry patients had similar EuroSCORE as randomized patients (4.0 ±
4.0 vs 3.8 ± 2.7) but higher SYNTAX Score (37.8 ± 13.3 vs 29.1 ± 11.4). Post-CABG
MACCE at three years was 16.4%. Table 1 lists individual MACCE components.
Stratification in low, intermediate, and high SYNTAX Score demonstrated a stepwise
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